Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
Gligorov, Joseph, Dr, Doval, Dinesh, MD, Bines, José, MD, Alba, Emilio, Prof, Cortes, Paulo, MD, Pierga, Jean-Yves, Prof, Gupta, Vineet, MD, Costa, Rômulo, MD, Srock, Stefanie, MD, de Ducla, Sabine, DEA, Freudensprung, Ulrich, MSc, Mustacchi, Giorgio, Prof
Published in The lancet oncology (01.11.2014)
Published in The lancet oncology (01.11.2014)
Get full text
Journal Article